Pharmaceuticals News and Research

RSS

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

News outlets continued to follow UNITAID's recent announcement to create a patent pool aimed at lowering the cost of HIV/AIDS drugs for low- and middle-income countries. Though UNITAID's board "voted Monday to create a board to run the new patent pool, and set a target of having five AIDS drugs in the pool by mid-2010," the group "punted on the thorny issue of which countries outside of Africa to include in the pool," Forbes reports.

16 Dec 2009

A selection of today's opinions and editorials

On the campaign trail, Barack Obama vowed to take on the drug industry by allowing Americans to import cheaper prescription medicine. "We'll tell the pharmaceutical companies 'thanks, but no, thanks' for the overpriced drugs. ... On Tuesday, the matter came to the Senate floor -- and President Obama forgot the "no, thanks" part (Dana Milbank, 12/16).

16 Dec 2009

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.

16 Dec 2009

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Amendment to allow drug importation fails in Senate

A bipartisan plan to allow Americans to buy cheaper prescription drugs from suppliers in other countries, such as Canada, failed Tuesday in the Senate. The Wall Street Journal reports the two top supporters of the plan, Sens. Byron Dorgan, D-N.D., and John McCain, R-Ariz., said shopping overseas via the Internet and mail-order companies could save consumers up to $80 billion over a decade if their amendment were added to the health overhaul legislation.

16 Dec 2009

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% - benzoyl peroxide 5%. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.

16 Dec 2009

Biostar Pharmaceuticals to acquire a Xi'an-based medical equipment and nutrients manufacturer for $1.1M

Biostar Pharmaceuticals, Inc., a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has signed a letter of intent ("LOI') with a Xi'an-based medical equipment and nutrients manufacturer ("Acquiree") to acquire 100% of the Acquiree for $1.1 million in cash.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

16 Dec 2009

Biotage expands direct sales coverage

Biotage is expanding its direct sales coverage and will begin selling SPE products directly into non-pharma application areas within the UK starting January 18, 2010. Sales to non-pharmaceutical based markets and customers have previously been managed by a distributor.

16 Dec 2009

ProtoKinetix evaluates major European proposals to expand AAGP technology use

ProtoKinetix Inc. (PKTX) has been approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas.

16 Dec 2009

Pharmaceutical manufacturers controlling health reform debate, Senate disallows prescription drug import

The failure of the U.S. Senate to allow importation of prescription drugs to cut costs, much less the more effective direct bulk purchasing of prescription drugs, is just the latest example of how big industry controls the health reform debate, according to Consumer Watchdog.

16 Dec 2009

Thomson Reuters offers integrated clinical trial protocol and outcome information for customers

Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

16 Dec 2009

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

Cellular Dynamics International launches iCell Cardiomyocytes

Cellular Dynamics International (CDI) today announced the commercial launch of iCell(TM) Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Pharmaceuticals News and Research

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

More details emerge about UNITAID's plan for patent pool for HIV/AIDS drugs

A selection of today's opinions and editorials

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Amendment to allow drug importation fails in Senate

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Biostar Pharmaceuticals to acquire a Xi'an-based medical equipment and nutrients manufacturer for $1.1M

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Biotage expands direct sales coverage

ProtoKinetix evaluates major European proposals to expand AAGP technology use

Pharmaceutical manufacturers controlling health reform debate, Senate disallows prescription drug import

Thomson Reuters offers integrated clinical trial protocol and outcome information for customers

ThromboGenics completes enrollment in second microplasmin Phase III trial

Cellular Dynamics International launches iCell Cardiomyocytes

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence